Study details
Enrolling now
Low Dose Naltrexone for Pain in Patients With HIV
Emory University
NCT IDNCT05537935ClinicalTrials.gov data as of Apr 2026
Phase
Phase 4
Target enrollment
60
Study length
about 3.7 years
Ages
18–75
Locations
3 sites in GA
About this study
Researchers are testing whether low dose naltrexone can help reduce pain in people with HIV/AIDS. The trial will monitor CD4 counts as part of routine care to see if the medication improves immune function and reduces symptoms. This could be a new way to manage pain for people living with HIV.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Low Dose Naltrexone
PhasePhase 4
DrugLow Dose Naltrexone
Routeinjection
Primary goalChanges in Numerical Pain Score
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low12%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
NERVOUS SYSTEM
Drug routes
injection (Injection)
Endpoints
Primary: Changes in Numerical Pain Score
Secondary: Changes in Average pain Score, Changes in PROMIS pain Score
Body systems
Immune, Infectious